News on research and diagnostics for metabolic disorders and metabolic diseases.
In a study of genetic variants associated with glycated hemoglobin in a meta-analysis, researchers found a G6PD variant leading to deceptively low blood sugar levels.
The new company will develop microbiome diagnostics for multiple indications including inflammatory bowel disease and liver disorders.
The system is based on nuclear magnetic resonance spectroscopy, and is designed to capture and analyze over 228 metabolic biomarkers from a single blood sample.
The assay can also be used to assess a broad range of metabolic conditions, including pancreatic tumors, liver disease, acromegaly, and others.
The test on the Alinity platform is for use in the POC or clinical laboratory setting, and for the quantitative measurement of glucose in arterial and venous whole blood.
